Cardinal Health's Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here's How That Happened
Weitzman's equity reduction follows a 57% one-year stock price surge, leaving her with $18.3 million in direct holdings.
Cardinal Health's Pharmaceuticals Chief, Deborah Weitzman, transferred 7,354 shares of the company's stock in a recent SEC filing, despite the sale resulting in a net increase of 47% in her stake. The transaction, valued at $1.73 million based on the weighted average sale price of $235.45 per share, was executed on August 15. Following the sale, the post-transaction value of her holdings was calculated at $1.09 million, based on the closing price of $234.98 per share on August 18.
Cardinal Health, a global leader in healthcare services and products with a TTM revenue of $254.2 billion and a market cap of $55 billion, maintains a competitive edge through its integrated distribution network, expansive scale across pharmaceutical and medical segments, and robust relationships with diverse healthcare providers worldwide.
With 58,788 employees operating across 190 countries, the company serves as a crucial link in the healthcare supply chain, facilitating the delivery of care in both institutional and individual patient settings.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
